skip to the content

Clinical Trials

Rhabdomyosarcoma Study

COG #ARST0531, Randomized Study of Viscristine, Datinomycin and Cyclophosphamide (VAC) versus VAC Alternating with Vincristine and Irinotecan (VI) for patients with intermediate-Risk Rhabdomyosarcoma (RMS)

Protocol ID

07.10.134

Protocol Description

The current standard treatment for rhabdomyosarcoma is surgery to remove as much tumor as possible, chemotherapy  with vincristine, dactinomycin and cyclophosphamide (together called VAC therapy), and, for almost all tumors, radiation therapy. The overall goals of this study are:

  • to see if the new combination - VAC plus VI  (vincristine plus irinotecan) -  is better than the standard chemotherapy (VAC) alone for treating intermediate risk RMS
  • to compare the effects, good and/or bad, of a new combination (VAC plus VI) of chemotherapy
  • to compare a new schedule  for giving radiation therapy to the standard schedule
  • to compare the side effects of a slightly lower dose of cyclophosphamide to the higher standard dose

Eligibility Criteria

Children and adolescents with rhabdomyosarcoma

Primary Investigator(s)

  • Arlene Redner, MD

Contact Information

Christine Grabowski, CCRP
(718) 470-3401
grabowsk@lij.edu

Last Update

March 29, 2010
top
  • Bookmark this Page
  • Toggle Text Size
  • Print this Page
Search Children's Health:
top
top